Organic Process Research & Development 2008, 12, 1238–1244
Calcium Pantothenate. Part 3.1 Process for the Biologically Active Enantiomer of
the Same via Selective Crystallization and Racemization
Ludwik Synoradzki,*,† Halina Hajmowicz,† Jerzy Wisialski,† Arkadiusz Mizerski,‡ and Tomasz Rowicki†
Laboratory of Technological Processes, Faculty of Chemistry, Warsaw UniVersity of Technology, ul. Noakowskiego 3,
00-664 Warszawa, Poland, and Grodzisk Pharmaceutical Works Polfa Ltd., ul. Poniatowskiego 5,
05-825 Grodzisk Mazowiecki, Poland
Abstract:
industrial purposes. The fundamental requirement for such a
process is the existence of conglomerates instead of the racemic
crystals in the solid phase. Fortunately, PTTCa possesses this
unique property. Particularly, its solvate containing four mol-
ecules of methanol and one of water crystallizes as a single
enantiomer from the racemic solution when seeded with
optically pure crystals. To date, the only drawback of the PTTCa
resolution has been the lack in the literature of an efficient direct
racemization method. According to the well-known procedures
the PTTCa racemization rather may be made after its hydrolysis
to pantolactone, which could be then racemized and reused in
(R,S)-PTTCa synthesis.7 Such a process, however, unreasonably
elongates the whole technology. Fortunately, an effective
procedure for direct PTTCa racemization has been developed
in our laboratory and hence allowing to overcome the problem.
Considering these facts we have undertaken an attempt to
develop an advantageous technology of calcium (R)-pantoth-
enate via direct resolution of the racemate. Since the research
has been carried out in co-operation with Grodzisk Pharma-
ceutical Works Polfa Ltd., the results obtained in the laboratory
have been subsequently realized in industrial scale reactors (up
to 3 m3), with considerable scale-up factors (crystallization 1500,
racemization 15000).
Optically pure calcium (R)-pantothenate has been obtained from
the racemic compound via direct fractional crystallization of the
single enantiomer. Efficient racemization of the biologically inactive
calcium (S)-pantothenate without its decomposition to pantolactone
has been developed, resulting in a simple, complete, and efficient
technology. The results elaborated in the laboratory have been
then successfully applied in the industrial scale process.
Introduction
Calcium (R)-pantothenate ((R)-PTTCa) and (R)-panthenol
are the most important commercial precursors of (R)-pantothenic
acid, a compound possessing a vitamin activity, denoted also
as vitamin B5. The significance of calcium (R)-pantothenate as
an ingredient of pharmaceutical and cosmetic compositions as
well as food and feed supplements caused the methods of its
production attract much attention since the first total synthesis
by Stiller.2 The most frequently used is the condensation of
ꢀ-alanine calcium salt with (R)-pantolactone,3 although the
separation of the racemic pantothenic acid with chiral amines
or by direct crystallization of its salts have also been described.4,5
Lately, the importance of biosynthetical methods has also
increased (Scheme 1).6
Among the methods shown in (Scheme 1), direct separation
of enantiomers is an extraordinarily attractive alternative for
Results and Discussion
Crystalline calcium pantothenate forms a number of poly-
morphs and solvates, depending on the solvent and temperature
applied for its crystallization.5b,8 Although the processes de-
scribed allow separation of the enantiomers of calcium pan-
tothenate, they suffer from some drawbacks when thoroughly
analyzed from the industrial point of view.5 Since the PTTCa
crystallizes as a methanol-water (4:1) solvate, the starting
solution must contain some water, with the minimum level
depending on the PTTCa concentration. For typical PTTCa
concentration of 30%, the solution should contain at least 0.9%
of water. The amount of water employed in the described
processes was slightly over the minimum to achieve satisfactory
yield of the product, since an increase of water content
simultaneously increases the PTTCa solubility. We have found
the process with such low water concentration to be, however,
* To
whom
correspondence
should
be
addressed.
E-mail:
Ludwik.Synoradzki@ch.pw.edu.pl. Fax: +48(22)6255317.
† Warsaw University of Technology.
‡ Grodzisk Pharmaceutical Works Polfa Ltd.
(1) For parts 1 and 2 see, respectively, (a) Rowicki, T.; Synoradzki, L.;
Włostowski, M. Ind. Eng. Chem. Res. 2006, 45, 1259–1265. (b)
Synoradzki, L.; Rowicki, T.; Włostowski, M. Org. Process Res. DeV.
2006, 10, 103–108.
(2) Stiller, E. T.; Harris, S. A.; Finkelstein, J.; Keresztesy, J. C.; Folkers,
K. J. Am. Chem. Soc. 1940, 62, 1785–1790.
(3) Paust, J.; Pfohl, S.; Reif, W.; Schmidt, W. Liebigs Ann. Chem. 1978,
1024–1029.
(4) (a) Kuhn, N.; Wieland, T. Chem. Ber. 1940, 73, 971. (b) Kuhn, N.;
Wieland, T. Chem. Ber. 1940, 73, 1134. (c) Stiller, E. T.; Wiley, P. F.
J. Am. Chem. Soc. 1941, 63, 1237.
(5) (a) Okuda, N.; Kuniyoshi, I.; Tsukamoto, H. GB Patent 1,124,619,
1968; Chem. Abstr. 1968, 69, 95968h. (b) Inagaki, M. Chem. Pharm.
Bull. 1977, 25, 1001–1009.
(6) See for example: (a) Hikichi, Y.; Moriya, T.; Nogami, I.; Miki, H.;
Yamaguchi, T. EP Patent 590,857, 1994; Chem. Abstr. 1994, 121,
55989b. (b) Nishimura, S.; Miki, H.; Matsumoto, J.; Shibutani, K.;
Yada, H. WO Patent 96/33283, 1996; Chem. Abstr. 1997, 126, 6565e.
(c) Moriya, T.; Hikichi, Y.; Moriya, Y.; Yamaguchi, T. WO Patent
97/10340, 1997; Chem. Abstr. 1997, 126, 263217d. (d) Yocum, R.;
Patterson, T.; Pero, J. G.; Hermann, T. WO Patent 02/061,108, 2002;
Chem. Abstr. 2002, 137, 15936g. (e) Beck, C.; Harz, H.-P. WO Patent
02/072,857, 2002; Chem. Abstr. 2002, 137, 231482x.
(7) (a) Klein, H. C.; Kapp, R. U.S. Patent 2,688,027, 1954; Chem. Abstr.
1955, 49, 13289f. (b) Klein, H. C.; Kapp, R. U.S. Patent 2,743,284,
1956; Chem. Abstr. 1956, 50, 16838e. (c) Garbarini, S. M.; Manz,
W. K.; McCormick, J. R. D. U.S. Patent 2,789,987, 1957; Chem. Abstr.
1957, 51, 12965g.
(8) Inagaki, M.; Tukamoto, H.; Akazawa, O. Chem. Pharm. Bull. 1976,
24, 3097–3102.
1238
•
Vol. 12, No. 6, 2008 / Organic Process Research & Development
10.1021/op800189g CCC: $40.75
2008 American Chemical Society
Published on Web 11/01/2008